Drug Trial Radar · NCT06900049
Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Sep 20, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 28, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 4 years, up to 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51 skipping therapy.
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
LE051Drug
LE051 dose escalation : dose 1 and dose 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of AEs, SAEsTime frame: from day 1 to week 52 after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.